Literature DB >> 17476302

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent.

J Probst1, B Weide, B Scheel, B J Pichler, I Hoerr, H-G Rammensee, S Pascolo.   

Abstract

The development of new treatments in the post-genomic era requires methods for safe delivery of foreign genetic information in vivo. As a transient, natural and controllable alternative to recombinant viruses or plasmid DNA (pDNA), purified or in vitro transcribed messenger RNA (mRNA) can be used for the expression of any therapeutic protein in vitro and in vivo. As it has been shown previously, the simple injection of naked mRNA results in local uptake and expression. We show here that this process, in the skin, can greatly be modulated according to the injection solution composition and blocked by an excess of competing nucleic acids or a drug affecting cytosolic mobility. Different cell types at the site of injection can take up the foreign nucleic acid molecules and the protein translated from this is detected for no more than a few days. To test this gene transfer method in humans, we produced in vitro transcribed mRNA under good manufacturing practice (GMP) conditions in a dedicated facility. After injection into the human dermis, we could document the translation of the exogenous mRNA. Our results pave the way toward the use of mRNA as a vehicle for transient gene delivery in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17476302     DOI: 10.1038/sj.gt.3302964

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  63 in total

1.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Authors:  Susanne M Rittig; Maik Haentschel; Katrin J Weimer; Annkristin Heine; Martin R Muller; Wolfram Brugger; Marius S Horger; Olga Maksimovic; Arnulf Stenzl; Ingmar Hoerr; Hans-Georg Rammensee; Tobias A W Holderried; Lothar Kanz; Steve Pascolo; Peter Brossart
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

2.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

Review 3.  mRNA: A Novel Avenue to Antibody Therapy?

Authors:  Thomas Schlake; Moritz Thran; Katja Fiedler; Regina Heidenreich; Benjamin Petsch; Mariola Fotin-Mleczek
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

Review 4.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

5.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 6.  Messenger RNA (mRNA) nanoparticle tumour vaccination.

Authors:  Kyle K L Phua; Smita K Nair; Kam W Leong
Journal:  Nanoscale       Date:  2014-07-21       Impact factor: 7.790

7.  PEGylation improves nanoparticle formation and transfection efficiency of messenger RNA.

Authors:  Senta Uzgün; Gabriela Nica; Corinna Pfeifer; Michele Bosinco; Kai Michaelis; Jean-François Lutz; Marc Schneider; Joseph Rosenecker; Carsten Rudolph
Journal:  Pharm Res       Date:  2011-05-19       Impact factor: 4.200

8.  In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles.

Authors:  Xingfang Su; Jennifer Fricke; Daniel G Kavanagh; Darrell J Irvine
Journal:  Mol Pharm       Date:  2011-04-01       Impact factor: 4.939

Review 9.  mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Authors:  Steffen Rausch; Christian Schwentner; Arnulf Stenzl; Jens Bedke
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.

Authors:  Kyle K L Phua; Kam W Leong; Smita K Nair
Journal:  J Control Release       Date:  2013-01-07       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.